| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
EXTENDED REPORT |
1 Division of Rheumatology, Department of Medical and Surgical Science, University of Padova, Italy
2 Department of Medicine B, Centre for Autoimmune Diseases, Sheba Medical Centre, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel
3 Specialty Laboratories, Santa Monica, CA, USA
4 Department of Clinical and Experimental Medicine, University of Padova, Italy
Correspondence to:
Correspondence to:
Dr A Doria, Division of Rheumatology, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy; adoria{at}unipd.it
Objective: To evaluate traditional and non-traditional risk factors for subclinical atherosclerosis in systemic lupus erythematosus (SLE).
Methods: A prospective cohort of 78 patients with SLE without overt atherosclerotic disease was studied. SLE clinical and laboratory parameters, disease activity and damage, treatment and traditional risk factors for atherosclerosis were evaluated. At baseline (T1) and after five years’ follow up (T2), the serum levels of anti-oxidised palmitoyl arachidonoyl phosphocholine (oxPAPC), anti-heat shock protein 65, and anti-ß2-glycoprotein I antibodies and C reactive protein were tested. At T2, intima-media thickness (IMT) was measured using duplex carotid sonography. Thickened intima, plaque, mean IMT (m-IMT), and maximum IMT (M-IMT) were assessed.
Results: A thickened intima was seen in 22/78 (28%) patients and plaque in 13/78 (17%). M-IMT and m-IMT were (mean (SD)) 0.77 (0.34) mm and 0.55 (0.15) mm, respectively. Patients with carotid abnormalities were significantly older, had higher blood pressure and total serum cholesterol levels, and had taken a higher prednisone cumulative dosage than those without any lesions. The carotid abnormalities were associated with renal disease and ECLAM >2 at T1, and with azathioprine treatment. In multivariate analysis, age and cumulative prednisone dose were associated with carotid abnormalities; age, hypertension, and anti-oxPAPC at T2 were correlated with higher M-IMT and m-IMT.
Conclusions: In patients with SLE some non-traditional risk factors for atherosclerosis were identified, the most important of which was the cumulative prednisone dose. The role of some traditional risk factors, such as age and hypertension, was also confirmed. The predictive value of the new immunological and inflammatory markers of atherosclerosis seems to be masked by some disease related features.
Keywords: atherosclerosis; carotid arteries; ultrasonics; systemic lupus erythematosus; risk factors
Abbreviations: aCL, anticardiolipin antibody; ACR, American College of Rheumatology; aPL, antiphospholipid antibody; ß2GPI, ß2-glycoprotein I; BP, blood pressure; CRP, C reactive protein; CVD, cardiovascular disease; ELISA, enzyme linked immunosorbent assay; HSP 65, heat shock protein 65; IMT, intima-media thickness; LA, lupus anticoagulant; LDL, low density lipoprotein; m-IMT, mean intima-media thickness; M-IMT, maximum intima-media thickness; oxPAPC, oxidised palmitoyl arachidonoyl phosphocholine; SLE, systemic lupus erythematosus
This article has been cited by other articles:
|
|
 |
|
  K de Leeuw, J Blaauw, A. Smit, C. Kallenberg, and M Bijl Vascular responsiveness in the microcirculation of patients with systemic lupus erythematosus is not impaired Lupus, November 1, 2008; 17(11): 1010 - 1017. [Abstract] [PDF]
|
|
|
|
|
|
J Frostegard Systemic lupus erythematosus and cardiovascular disease Lupus, May 1, 2008; 17(5): 364 - 367. [Abstract] [PDF]
|
|
|
|
|
|
A Doria and C Briani Lupus: improving long-term prognosis Lupus, March 1, 2008; 17(3): 166 - 170. [Abstract] [PDF]
|
|
|
|
|
|
R. Telles, C. Lanna, G. Ferreira, A. Souza, T. Navarro, and A. Ribeiro Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting Lupus, February 1, 2008; 17(2): 105 - 113. [Abstract] [PDF]
|
|
|
|
 |
|
 S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhatt, R. Handa, G. Gulati, S. Sharma, R. Pandey, P. Aggarwal, L. Ramakrishnan, and S. Shankar Peripheral vascular disease in systemic lupus erythematosus Lupus, September 1, 2007; 16(9): 720 - 723. [Abstract] [PDF]
|
|
|
|
|
|
H. Der, G. Kerekes, K. Veres, P. Szodoray, J. Toth, G. Lakos, G. Szegedi, and P. Soltesz Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome Lupus, July 1, 2007; 16(7): 497 - 503. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ahmad, J. Shelmerdine, H. Bodill, M. Lunt, M. G. Pattrick, L. S. Teh, R. M. Bernstein, M. G. Walker, and I. N. Bruce Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype Rheumatology, June 1, 2007; 46(6): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaiamnuay, A. M Bertoli, J. M Roseman, G. McGwin, M. Apte, S. Duran, L. M Vila, J. D Reveille, and G. S Alarcon African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV) Ann Rheum Dis, May 1, 2007; 66(5): 618 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Garcia-Carrasco, R.O. Escarcega, J. Perez-Terron, A. Ramirez, M. Munoz-Guarneros, A. Beltran, B. Perez-Cuevas, A. Lopez-Colombo, and R. Cervera Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease Lupus, April 1, 2007; 16(4): 298 - 301. [Abstract] [PDF]
|
|
|
|
 |
|
 R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Szekanecz and Y Shoenfeld Lupus and cardiovascular disease: the facts Lupus, November 1, 2006; 15(11_suppl): 3 - 10. [Abstract] [PDF]
|
|
|
|
|
|
I N Bruce The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 23 - 26. [Abstract] [PDF]
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]
|
|
|
|
|
|
M McMahon, J Grossman, W Chen, and B H Hahn Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 59 - 69. [Abstract] [PDF]
|
|
|
|
|
|
K De Leeuw, B Freire, A J Smit, H Bootsma, C G Kallenberg, and M Bijl Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus Lupus, October 1, 2006; 15(10): 675 - 682. [Abstract] [PDF]
|
|
|
|
|
|
A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus Rheumatology, October 1, 2006; 45(suppl_4): iv8 - iv13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Bagi, P Hamar, M Kardos, and A Koller Lack of flow mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice Lupus, June 1, 2006; 15(6): 326 - 334. [Abstract] [PDF]
|
|
|
|
|
|
L R Lopez, M Salazar-Paramo, C Palafox-Sanchez, B L Hurley, E Matsuura, and I Garcia-De La Torre Oxidized low-density lipoprotein and {beta}2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis Lupus, February 1, 2006; 15(2): 80 - 86. [Abstract] [PDF]
|
|
|
|
|
|
F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N. Bruce 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus Rheumatology, December 1, 2005; 44(12): 1492 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shoenfeld, R. Gerli, A. Doria, E. Matsuura, M. M. Cerinic, N. Ronda, L. J. Jara, M. Abu-Shakra, P. L. Meroni, and Y. Sherer Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases Circulation, November 22, 2005; 112(21): 3337 - 3347. [Full Text] [PDF]
|
|
|
|
|
|
K. T. Ho, C. W. Ahn, G. S. Alarcon, B. A. Baethge, F. K. Tan, J. Roseman, H. M. Bastian, B. J. Fessler, G. McGwin Jr, L. M. Vila, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events Rheumatology, October 1, 2005; 44(10): 1303 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Doria and P Sarzi-Puttini Heart, rheumatism and autoimmunity: an old intriguing link Lupus, September 1, 2005; 14(9): 643 - 645. [PDF]
|
|
|
|
|
|
A Tincani, C Biasini-Rebaioli, R Cattaneo, and P Riboldi Nonorgan specific autoantibodies and heart damage Lupus, September 1, 2005; 14(9): 656 - 659. [Abstract] [PDF]
|
|
|
|
|
|
A Doria, L Iaccarino, P Sarzi-Puttini, F Atzeni, M Turriel, and M Petri Cardiac involvement in systemic lupus erythematosus Lupus, September 1, 2005; 14(9): 683 - 686. [Abstract] [PDF]
|
|
|
|
|
|
I N Bruce Atherogenesis and autoimmune disease: the model of lupus Lupus, September 1, 2005; 14(9): 687 - 690. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Brotman, J. P. Girod, M. J. Garcia, J. V. Patel, M. Gupta, A. Posch, S. Saunders, G. Y. H. Lip, S. Worley, and S. Reddy Effects of Short-Term Glucocorticoids on Cardiovascular Biomarkers J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3202 - 3208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jimenez, M. A. Garcia-Criado, D. Tassies, J. C. Reverter, R. Cervera, M. R. Gilabert, D. Zambon, E. Ros, C. Bru, and J. Font Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome Rheumatology, June 1, 2005; 44(6): 756 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Marasini, M De Monti, and G Ghilardi Risk factors for accelerated atherosclerosis in patients with systemic lupus erythematosus Ann Rheum Dis, January 1, 2005; 64(1): 163 - 164. [Full Text] [PDF]
|
|
|
|
|
|
Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective? Circulation, October 26, 2004; 110(17): 2552 - 2558. [Full Text] [PDF]
|
|
|
|
|
|
I. N Bruce Coronary heart disease (CHD) in lupus: round up the usual suspects? Lupus, August 1, 2004; 13(8): 557 - 560. [PDF]
|
|
|
|
|
|
C. Gorman and D. Isenberg Atherosclerosis and lupus Rheumatology, August 1, 2004; 43(8): 943 - 945. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wurzel, B. I. Goldman, A. Doria, Y. Shoenfeld, P. Pauletto, F. Violi, L. Loffredo, D. Ferro, F. Pezzetta, L. Mascitelli, et al. Premature Coronary Disease in Systemic Lupus N. Engl. J. Med., April 8, 2004; 350(15): 1571 - 1575. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
